Icosavax (ICVX) executive Simpson sold 66,764 shares for $598K at $8.96 under a 10b5-1 plan
Insider transactions reported
Adam K. Simpson (executive at Icosavax Inc., ICVX) reported that they sold 66,764 shares for $598K at $8.96, and acquired 14,369 shares at $0.84 between Dec 21, 2022 and Dec 23, 2022. After these transactions the filing shows 239,474 shares held directly.
- Reporting person
- Simpson Adam K.
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Dec 21, 2022 | Open-market sale (S) | Common Stock1, 2 | -66,764 | $8.96 | $598K | 225,105 direct |
| Dec 23, 2022 | Exercise or conversion of a derivative (M) | Common Stock | +14,369 | $0.84 | $12.1K | 239,474 direct |
Options and other derivatives
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Dec 23, 2022 | Exercise or conversion of a derivative (M) | Stock Option (Right to Buy)On 14,369 Common Stock3 | -14,369 | - | - | 33,527 direct |
Holdings before and after
- Common Stock: 291,869 to 239,474 direct
- Stock Option (Right to Buy): 47,896 to 33,527 direct
Other positions listed
- Common Stock: 531,576 indirect, By family trust
- Common Stock: 129,032 indirect, By family trust
- Common Stock: 129,032 indirect, By family trust
Footnotes from the filing
- 1. Represents the sale by the Reporting Person, pursuant to a Rule 10b5-1 trading plan, of a portion of the shares of the Issuer purchased by the Reporting Person via exercise of incentive stock options during 2022. These shares are being sold by the Reporting Person prior to the end of 2022 in order to trigger a disqualifying disposition of such shares and to eliminate the alternative minimum tax that would otherwise arise as a result of the Reporting Person's exercise of such incentive stock options during 2022, with the remainder of the purchased shares continued to be held by the Reporting Person.
- 2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.54 to $9.41. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- 3. 25% of the shares subject to the option vested on 2/21/2021, and 1/48th of the shares subject to the option vest monthly thereafter.
Transaction codes in this filing
- Open-market sale:
- Code S marks a sale in the open market or a private deal. The insider received cash for these securities.
- Exercise or conversion of a derivative:
- Code M marks the exercise or conversion of an option or other derivative under an exempt plan.
FAQ
What did Simpson report in this ICVX Form 4?
Adam K. Simpson (executive at Icosavax Inc., ICVX) reported that they sold 66,764 shares for $598K at $8.96, and acquired 14,369 shares at $0.84 between Dec 21, 2022 and Dec 23, 2022. After these transactions the filing shows 239,474 shares held directly.
How many ICVX shares does Simpson hold after this filing?
The filing shows 239,474 shares held directly after the reported transactions. Form 4 reports only the positions it lists, so this may not be every holding.
Was this ICVX insider sale made under a 10b5-1 plan?
The filing's footnotes mention a Rule 10b5-1 trading plan. Such a plan sets the terms of future trades in advance.
What does transaction code S mean on an SEC Form 4?
Code S marks a sale in the open market or a private deal. The insider received cash for these securities.
Historical context for ICVX
Earlier insider filings at ICVX
- Dec 16, 2022SEC Form 4: Holtzman Douglas sold $218,963 worth of shares (19,648 units at $11.14)
- Nov 15, 2022SEC Form 4 filed by Bekiroglu Elizabeth
- Nov 15, 2022SEC Form 4 filed by Russo Thomas Joseph
- Nov 14, 2022SEC Form 4 filed by Holtzman Douglas
- Nov 14, 2022SEC Form 4 filed by Cearley Cassia
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2021
Follow ICVX and get a push notification the moment its next story breaks.